The specter of generic challenges has repeatedly loomed around copyright’s iconic drug, Sildenafil, raising questions about the outlook of similar drug ventures. While early periods saw substantial returns, the intellectual property expiration has created the door for less expensive alternatives, possibly reducing revenue and creating a genuine d